Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 24, 2019October 24, 2019

Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo

News

A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial ... Read more

September 13, 2019

Partnership Aims to Identify DLBCL Patients Likely to Benefit from ADCT-402

News

ADC Therapeutics announced it partnered with Freenome to identify biomarkers that can help to predict which diffuse large B-cell lymphoma (DLBCL) patients are most likely to respond to ADCT-402 (loncastuximab tesirine), ... Read more

September 10, 2019

Biosimilar ABP 798 Shows Similar Safety and Efficacy to Rituxan in Phase 3 Trial for Non-Hodgkin’s Lymphoma

News

ABP 798, a biosimilar to Rituxan (rituximab), is showing comparable efficacy results to its original product in a Phase 3 trial for non-Hodgkin’s lymphoma patients, the treatment’s co-developers, Amgen and Allergan, have ... Read more

September 5, 2019

Inherited BRCA2 Mutations Linked to Risk of Non-Hodgkin’s Lymphoma in Children

News

Inherited mutations in the DNA repair gene BRCA2 — a well-known risk factor for breast and ovarian cancers in adults — also show a significant association with non-Hodgkin’s lymphoma in children ... Read more

August 27, 2019

Cirmtuzumab-Imbruvica Combo Trial Enrolling CLL, SLL Patients for Phase 2

News

Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of ... Read more

August 20, 2019

Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma

News

Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular ... Read more

August 2, 2019August 2, 2019

First Patient Dosed in Trial Testing Abexinostat-Imbruvica Combo for Advanced Lymphomas

News

Xynomic Pharma has initiated patient dosing in a Phase 1/2 trial testing its investigational therapy abexinostat, in combination with Imbruvica (ibrutinib), as a treatment for people with mantle cell lymphoma (MCL) and ... Read more

July 30, 2019August 26, 2019

FDA Approves Rituxan Biosimilar Ruxience for Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for all non-Hodgkin’s lymphoma indications of its reference product, the company announced. The therapy ... Read more

July 23, 2019

NantKwest Launches Phase 1 Trial to Assess Investigational Cell Therapy for B-cell Lymphomas

News

NantKwest is launching the first-in-human Phase 1 clinical trial assessing the effects of its investigational CD19 t-haNK cell therapy in people with locally advanced B-cell lymphoma. The trial follows the ... Read more

July 12, 2019July 12, 2019

Dosing Begins in Study of TP-0903, With or Without Imbruvica, for Advanced CLL and SLL

News

Dosing with the investigational therapy TP-0903 has begun in patients with previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in an ongoing Phase 1/2 trial, its developer, Tolero Pharmaceuticals, announced. ... Read more